Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 28;13(1):5.
doi: 10.1186/s12993-017-0123-6.

Cognitive-enhancing and antioxidant activities of the aqueous extract from Markhamia tomentosa (Benth.) K. Schum. stem bark in a rat model of scopolamine

Affiliations

Cognitive-enhancing and antioxidant activities of the aqueous extract from Markhamia tomentosa (Benth.) K. Schum. stem bark in a rat model of scopolamine

Radu Ionita et al. Behav Brain Funct. .

Abstract

Background: Plants of the genus Markhamia have been traditionally used by different tribes in various parts of West African countries, including Cameroun. Markhamia tomentosa (Benth.) K. Schum. (Bignoniaceae) is used as an antimalarial, anti-inflammatory, analgesic, antioxidant and anti-Alzheimer agent. The current study was undertaken in order to investigate its anti-amnesic and antioxidant potential on scopolamine-induced cognitive impairment and to determine its possible mechanism of action.

Methods: Rats were pretreated with the aqueous extract (50 and 200 mg/kg, p.o.), for 10 days, and received a single injection of scopolamine (0.7 mg/kg, i.p.) before training in Y-maze and radial arm-maze tests. The biochemical parameters in the rat hippocampus were also assessed to explore oxidative status. Statistical analyses were performed using two-way ANOVA followed by Tukey's post hoc test. F values for which p < 0.05 were regarded as statistically significant.

Results: In the scopolamine-treated rats, the aqueous extract improved memory in behavioral tests and decreased the oxidative stress in the rat hippocampus. Also, the aqueous extract exhibited anti-acetylcholinesterase activity.

Conclusions: These results suggest that the aqueous extract ameliorates scopolamine-induced spatial memory impairment by attenuation of the oxidative stress in the rat hippocampus.

Keywords: Acetylcholinesterase; Alzheimer’s disease; Markhamia tomentosa stem bark extract; Oxidative stress; Scopolamine; Spatial memory.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
HPLC chromatogram the aqueous extract from Markhamia tomentosa stem bark. The major identified compounds were rozmarinic acid, (+)-catechin, procyanidin dimer, (−)-epicatechin and cyanidin trimmers
Fig. 2
Fig. 2
Effects of the aqueous extract from Markhamia tomentosa stem bark (50 and 200 mg/kg) in the Y-maze on spontaneous alternation  % (a) and on the working memory errors (b) and the reference memory errors (c) during 7 days training in radial arm-maze task in the scopolamine-treated rats. Values are mean ± SEM (n = 5 animals per group). For Tukey’s post hoc analysis—##Control vs. Sco: p < 0.001, #Sco vs. Sco+ME (50 mg/kg): p < 0.01 and ##Sco vs. Sco+ME (200 mg/kg): p < 0.001 (a), ##Control vs. Sco: p < 0.0001, #Sco vs. Sco+ME (50 mg/kg): p < 0.001 and ##Sco vs. Sco+ME (200 mg/kg): p < 0.0001 (b) and #Control vs. Sco+ME (50 mg/kg): p < 0.001, ##Control vs. Sco+ME (50 mg/kg): p < 0.001, ##Sco vs. Sco+ME (50 mg/kg): p < 0.0001 and ###Sco vs. Sco+ME (200 mg/kg): p < 0.0001 (c)
Fig. 3
Fig. 3
Effects of the aqueous extract from Markhamia tomentosa stem bark (50 and 200 mg/kg) on AChE (a), SOD (b) and GPX (c) specific activities, on reduced GSH (d), protein carbonyl (e) and MDA (f) levels in the scopolamine-treated rats. Values are mean ± SEM. (n = 5 animals per group). For Tukey’s post hoc analysis—#Control vs. Sco: p < 0.01, #Sco vs. Sco+ME (50 mg/kg): p < 0.01 and ##Sco vs. Sco+ME (200 mg/kg: p < 0.001 (a), ###Control vs. Sco: p < 0.0001, ##Sco vs. Sco+ME (50 mg/kg): p < 0.001 and ###Sco vs. Sco+ME (200 mg/kg): p < 0.0001 (b), ###Control vs. Sco: p < 0.0001, ###Control vs. Sco+ME (50 mg/kg): p < 0.0001, ###Control vs. Sco+ME (200 mg/kg): p < 0.0001, #Sco vs. Sco+ME (50 mg/kg): p < 0.01 and ##Sco vs. Sco+ME (200 mg/kg): p < 0.001 (c), #Control vs. Sco: p < 0.01, #Sco vs. Sco+ME (50 mg/kg): p < 0.01 and ##Sco vs. Sco+ME (200 mg/kg): p < 0.001 (d), ##Control vs. Sco: p < 0.0001, ##Sco vs. Sco+ME (50 mg/kg): p < 0.0001 and ###Sco vs. Sco+ME (200 mg/kg): p < 0.00001 (e) and ##Control vs. Sco: p < 0.0001, ##Sco vs. Sco+ME (50 mg/kg): p < 0.0001 and ###Sco vs. Sco+ME (200 mg/kg): p < 0.00001 (f)
Fig. 4
Fig. 4
Pearson’s correlation between the spontaneous alternation percentage vs. AChE (a), spontaneous alternation percentage vs. MDA (b), working memory errors vs. AChE (c), working memory errors vs. MDA (d), reference memory errors vs. AChE (e) and reference memory errors vs. MDA (f) in control group (filled circle), scopolamine alone treated-group (filled square), Sco+ME (50 mg/kg) group (filled diamond) and Sco+ME (200 mg/kg) group (filled triangle)
Fig. 5
Fig. 5
Pearson’s correlation between SOD vs. MDA (a), GSH vs. MDA (b), protein carbonyl vs. MDA (c) and AChE vs. MDA (d) in control group (filled circle), scopolamine alone treated-group (filled square), Sco+ME (50 mg/kg) group (filled diamond) and Sco+ME (200 mg/kg) group (filled triangle)

Similar articles

Cited by

References

    1. Palop JJ, Mucke L. Network abnormalities and interneuron dysfunction in Alzheimer disease. Nat Rev Neurosci. 2016;17(12):777–792. doi: 10.1038/nrn.2016.141. - DOI - PMC - PubMed
    1. Ittner LM, Götz J. Amyloid-β and tau-a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12(2):67–72. doi: 10.1038/nrn2967. - DOI - PubMed
    1. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications. Expert Rev Neurother. 2008;8(11):1703–1718. doi: 10.1586/14737175.8.11.1703. - DOI - PMC - PubMed
    1. Araujo JA, Studzinski CM, Milgram NW. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Neuro Psychopharmacol Biol Psychiatr. 2005;29(3):411–422. doi: 10.1016/j.pnpbp.2004.12.008. - DOI - PubMed
    1. Inestrosa NC, Alvarez A, Pérez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J. Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996;16(4):881–891. doi: 10.1016/S0896-6273(00)80108-7. - DOI - PubMed

LinkOut - more resources